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Background: When anti-tumour therapy is administered to a tumour-host environment,
an asymptotic tapering extremity of the tumour cell distribution is noticed. This
extremity harbors a small number of residual tumour cells that later lead to secondary
malignances. Thus, a method is needed that would enable the malignant population
to be completely eliminated within a desired time-frame, negating the possibility of
recurrence and drug-induced toxicity.
Methods: In this study, we delineate a computational procedure using the inverse
input-reconstruction approach to calculate the unknown drug stimulus input, when
one desires a known output tissue-response (full tumour cell elimination, no excess
toxicity). The asymptotic extremity is taken care of using a bias shift of tumour-cell
distribution and guided control of drug administration, with toxicity limits enforced,
during mutually-synchronized chemotherapy (as Temozolomide) and immunotherapy
(Interleukin-2 and Cytotoxic T-lymphocyte).
Results: Quantitative modeling is done using representative characteristics of rapidly
and slowly-growing tumours. Both were fully eliminated within 2 months with checks
for recurrence and toxicity over a two-year time-line. The dose-time profile of the
therapeutic agents has similar features across tumours: biphasic (lymphocytes),
monophasic (chemotherapy) and stationary (interleukin), with terminal pulses of the
three agents together ensuring elimination of all malignant cells. The model is then
justified with clinical case studies and animal models of different neurooncological
tumours like glioma, meningioma and glioblastoma.
Conclusion: The conflicting oncological objectives of tumour-cell extinction and host
protection can be simultaneously accommodated using the techniques of drug input
reconstruction by enforcing a bias shift and guided control over the drug dose-time
profile. For translational applicability, the procedure can be adapted to accommodate
varying patient parameters, and for corrective clinical monitoring, to implement full
tumour extinction, while maintaining the health profile of the patient.
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Though there has been considerable efforts in exploring newer modalities of cancer
treatment in the last several decades, hopes have been belied by a fundamental reason,
though not fully appreciated, namely the difficulty of eradicating a tumour mass due to
the nature of reaction kinetics that govern the interaction of tumour cells with the
therapeutic agents administered. These interactions are governed by first-order reaction
processes (chemotherapy) and enzyme saturation kinetics (immunotherapy) [1]. Both
these prescribed treatments cause an exponential decay of the tumour cell population
leaving a finite definitive number of tumour cells at the asymptotic extremity of tumour
versus drug distribution curve. By its very nature, an asymptotic tail implies the tumour
cell population curve will contact the horizontal axis and become zero only when either
the time duration or the drug dose is infinite. For instance, a typical tumour may have
1010 cells, and the surviving fraction, SF, of tumour cells after administration of a drug
concentration D is SF = exp (−α D). Using the standard values of α = 0.02 and D =
150 mg for bleomycin (maximum dose tolerated) [2], the equation yields 1,765 cells
surviving. This elucidates why many tumours recur, after appearing to initially shrink
or regress under therapy.
An imminent question in neurooncology is the efficacy of the drug to be able to cross
the “blood–brain barrier” (BBB) to enter the brain. A recent progress is the develop-
ment of DNA alkylating drugs such as Temozolomide (TMZ) which while being highly
targeted, can effectively cross the BBB [3]. However TMZ is known to be contraindi-
cated in some cases such as in patients with severe myelosuppression. A few other
common side effects are nausea and vomiting which are self-limiting or readily
controlled with standard therapy. Temozolomide is a teratogenic compound and thus
should not be used during pregnancy. It might very rarely leads to acute respiratory
failure. However, no drug-related adverse CNS effects or alopecia are known to occur
with temozolomide [3].
To complement the effects of chemotherapy, immunotherapy, is also being consid-
ered for its synergistic carcinolytic effects. Recent incisive findings of Wheeler et al. [4]
indicate that a combinatorial therapy design utilizing immunotherapy with chemother-
apy reduces tumour volume by 50% and appreciably extends the average 1 year survival
duration of glioblastoma patients, which cannot be done by either chemotherapy or im-
munotherapy alone. An important aspect of immunotherapy is to utilize cytotoxic
T-lymphocytes (CTL) which are CD8 + T cells, that are known to be carcinolytic. Acti-
vated CTL can be generated by administering immunomodulating factors,. This can be
done by two means: (i) administering cytokines such as Interleukin-2 (IL-2) which can
cross the blood–brain barrier, and (ii) injecting cellular agents such as tumour-
infiltrating lymphocytes (TIL) prepared beforehand by sensitizing T-cells of the patient’s
blood against the tumour (biopsy tissue). These TILs proceed satisfactorily to the
tumour mass in the brain parenchyma. Also, IL-2 is well known to stimulate recruit-
ment and proliferation of cytotoxic T-lymphocytes, such as CD8+ T cells, suggesting a
novel neurooncological approach [5].
A critical aspect of anticancer therapy is maintaining protection of the healthy (non-
malignant) cells of the affected as well as neighboring unaffected tissue within tolerable
limits. In cases of toxicity due to high doses of chemotherapeutic or immunotherapeu-
tic agents, the patient may succumb to opportunistic pathogenic infection occurring
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leading to septicemia, multi-organ failure and eventually death. The normal cell protec-
tion can be characterized by the concentration of circulating lymphocyte population in
the blood [6]. These lymphocytes generate antibodies against infection, activate B-cells,
T-cells and Natural Killer (NK) cells against pathogens. For ensuring that normal tissue
protection is maintained during therapy, we have applied constraints or bounds in the
feedback function of the drug dosages in the therapy control system, so that there
is always a self-regulated judicious combination of the dose-and-time schedule of the
antitumour agents, such that the circulating lymphocytes do not fall below a tolerable
threshold value. The therapeutic agents have compensatory effects on the lymphocytes,
as the chemotherapy input damages the lymphocytes, while the immunotherapy drug
protects the lymphocytes. A measure of the tissue damage inflicted by antitumour agents
can be described by the toxicity cost function J, wherein cytotoxicity, a second-order effect
[7], depends on second-power of drug-dosage:




Here u1, u2, …. are the levels of the different antitumour agents, while B1, B2,
…. are the weighting factors of the different agents. We use this principle to suit-
ably orchestrate the temporal schedule of the drugs, so that that toxicity is
minimized.
We may mention that various attempts at modeling the immune system inter-
action with neoplastic tumours have been previously made [8-10]. These models
have efficiently characterized the computational dynamics of drug versus tumour
interaction via the immune system. Using the background of the existing models,
in our model we have tried to delineate the kinetics and dynamics of immune
modulation responsible for the paradoxical clinical phenomenon of tumour dor-
mancy, prolonged arrest and oscillations of tumour-size [11]. A unitary approach
to the dual behaviour of tumour progression and tumour regression has recently
been explained [12], where the neoplastic process has been elucidated as systems
biology-based abnormality. The tumour regression approach that we report in the
present work is to our knowledge, the first endeavor to elucidate a quantitative
methodology to delineate the dose-time profile of administration of the antitumour
agents (chemotherapy, interleukin, lymphocytes) with neuroncological cases as
examples, so as to enforce the tumour cell population to zero, thus enabling full
tumour elimination. For this, we develop an interdisciplinary approach, utilizing
input reconstruction analysis and bias shift.Methods
Inverse construction of drug input for obtaining desired tumour response
In conventional quantitative mathematical models, the inputs in terms of therapeutic
agent concentration are substituted in the model (differential equations of tumour cell
population) to solve for tumour cell population at different dosages and time durations.
This is a “forward direct solution”, whereby, given the stimulus or input (concentra-
tions of the N number of drugs, DN), one calculates the response or output (remaining
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cell-drug interactions (X, Y, Z):
DN drugsð Þ→X→Y→Z→T tumourð Þ ð1Þ
Typically, in eq. (1), the investigator starts with varying dosages of the drug combina-tions DN, and obtains the resulting values of the surviving tumour cell population T as
one changes the dosage profiles of the drugs. Using this information, the specific dosing
schedule of the drugs, DN
† is selected, which would lead to minimization of the number
of remaining cancer cells, Tmin. The sites X, Y and Z are referred respectively as intrin-
sic (input), intermediate and extrinsic (output) compartments (Figure 1). The extrinsic
compartment Z is related to the external output of the therapy system (i.e. remnant
tumour cell population T). Likewise, the intrinsic compartment X relates to the internalINVERSE SOLUTION:                                                                                                               STIMULUS
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Figure 1 Functional design of the therapeutic system using the Stimulus-Reconstruction approach.
Output compartment (Tumour cell compartment): The state T (tumour cell population) is driven by state L
(cytotoxic T-cell population in blood) and state M (chemotherapy drug temozolomide concentration in
blood). Goal of system design is that the tumour cell population in this compartment decrease to a desired
definitive value Td (which is aimed to be zero); solving this compartment we arrive at L* and M* which are
desired values respectively for cytotoxic T-cell population in blood and temozolomide concentration in
blood required for complete tumour elimination. Intermediate compartment (Cytotoxic T-cell compartment):
State L (cytotoxic T-cell population in blood) is driven by state I (interleukin-2 concentration in blood) and by
state vL (daily dosage of tumour-infiltrating leucocyte injection as immunotherapy). Solving this compartment,
we get I* and vL* which are the desired values respectively of interleukin-2 concentration in blood and dosage
of tumour-infiltrating leucocyte required for tumour elimination. Input compartment-I (Interleukin-2 injection
compartment): State I (Interleukin-2 concentration in blood) is driven by state vI (daily dosage of interleukin-2
injection as immunotherapy). By solving this compartment, we arrive at vI*, the desired value of interleukin-2
dosage required. Input compartment-II (Temozolomide injection compartment): State M (temozolomide
concentration in blood) is driven by state vM (daily dosage of temozolomide injection as chemotherapy). Solving
this compartment, we arrive at vM*, the desired value of temozolomide dosage required. Input compartment-III
(Tumour-infiltrating leucocyte injection compartment): This furnishes daily dosage of tumour infiltrating leucocyte
injection required, and is constructed from cytotoxic T-cell compartment above. Collateral compartment (normal
tissue protection): This compartment comprises of circulating lymphocytes concentration in blood (C) and
natural killer cell concentration in blood (N) which guard normal tissue against infection that may be caused
by toxicity side-effect induced by the therapeutic agents.
Kapoor et al. Theoretical Biology and Medical Modelling 2013, 10:68 Page 5 of 34
http://www.tbiomed.com/content/10/1/68control input coming from the therapy system, i.e., administration of therapeutic
agents, DN.
To circumvent the problem of Tmin i.e. the residual cancer cells that may cause tumour
recurrence, we suggest the “backward inverse solution”, whereby one starts first with the de-
sired objective, i.e. response or output (viz., tumour cell population becoming zero in a desired
finite time period, t1), and, then work backwards through the sequential stages inversely,
namely Z, Y, X to derive the drug concentrations to attain the above mentioned objectives:
T tumourð Þ→Z→Y→X→DN drugsð Þ ð2Þ
So, in the equation (2), one puts T = 0 at time t1, which is used to calculate the tem-poral profile of dosages of the combination drugs (DN
† ). Thus, if one administers the
temporal dosages profile (DN
† ), then the tumour cell population definitively becomes
zero in time t1, indicating tumour elimination. The perspective of inverse analysis ap-
proach [eq. (2)] has been well used in other fields in the form of stimulus reconstruc-
tion approach. This enables one to accurately quantify an antecedent unknown
stimulus, using the knowledge of the observed response pattern. In our case, the meth-
odology enables one to reconstruct the input drug stimulus, which will accurately
produce complete tumour elimination as the output in finite time.
Problem of asymptotic drug reaction kinetics
The cell-drug interactions are governed by first-order chemical reaction rate kinetics
[1] using which the tumour cell population T at time t decreases exponentially in a
monotonic manner:
T ¼ T 0 exp −κT tð Þ; i:e: T′þ κTT ¼ 0: ð3Þ
where T0 is initial population, T′ is the time derivative of T, and κT is the drug’s
cytotoxic rate constant (Figure 2A). As explained before, there persists asymptotically a
residual tumour cell population, which now needs to be dealt with. Hence, one needs a
procedure to ensure that the monotonically decreasing curve contacts the horizontal
axis at a definite finite time point tp. In other words, the cell population curve should
be dynamically modulated by therapy so that its trajectory is actively guided, enabling
the curve to contact the horizontal axis at time tp.
As in the case of a biochemical reactor, conditions may arise where the synthesis rate
R following first-order reaction, needs to be controlled and stopped at a definitive time
[13]. To explore the possibility of inducing the reactor's processing to stop (i.e., R = 0),
one may omit the input feed of reactants which causes the reaction to slow, but not
become zero even after any length of time leaving a small asymptotic level of reaction
rate R persisting at a time t, since first-order kinetics indicates R′ + κ R = 0.
The asymptoticity in both the above cases is due to the fact that both the dynamic
equations are similar and first-order, viz. y′ + k y = 0. Here the y-axis denotes the system
parameter, as reaction rate or altitude, while the x-axis denotes time. The equation im-
plies that at infinite time, the curve meets the y-axis, if the coordinates at this meeting
point is t † and y †, then y † = 0, as t † =∞. Nevertheless, in the exponential systems
above, we elucidate that the systems dynamics can be halted in a finite time (i.e., y = 0,
at specific time tp), if one implements the concept of an adjustable or tunable bias shift,
denoted by y*. This enables the performance curve to approach a value y → y*
Figure 2 Implementation of Bias Shift in tumour cell population trajectory to ensure complete
elimination of tumour. (A) Under usual intervention by therapeutic agents, the elimination of the tumour
cell population T(t) is an exponentially decreasing curve, asymptotically approaching the time axis, so that
tumour cell population becomes zero at infinite time duration. There is always a number of malignant cells
in the exponential tail of the curve at any realistic time point, and the tumour recurs after the therapeutic
agents are stopped. (B) The procedure from control systems analysis of utilizing the methodology of Bias
Shift, for enabling the tumour cell population curve under therapy, so as to definitively attain zero cell
population (tumour extinction) within a specific time tp. The curve of T(t) intersects the time axis i.e.,
T(t) = 0, at the definitive time point P, by incorporating bias shift using a finite T* value.
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the curve trajectory intersects the time axis, and has an exact value y = 0 robustly, at a
definite time tp [point P, in Figure 2B]. We have earlier methodologically simulated and
validated realistically the procedure of bias shift, while respecting the requisite bounds
or constraints imposed on the system [14]; thereby the exponential curve was induced
to become zero within specific time interval, the error in the validation process being
within 2.5%.
Using bias shift as baseline regulating principle
The aim of control systems design is to enable the tumour cell population (state T) to
track and approach the T* value i.e. T→ T*, where T* has a chosen bias shift whose
value depends on the desired duration of tumour elimination, tp. From Figure 2B, the
curve T is the arc path ACPD.
T ¼ T 0 þ T ð Þ exp −κT tð Þ −T ;whereby; bias T ¼ −T0 exp −κT tp
 
=1– exp −κT tp
   ð4Þ
To enable the T curve to approach towards the T* value (bias shifted line L in
Figure 2B), we use the guided tracking principle of control systems analysis [15]. Actu-
ally, the tumour cell population T follows the curve from point A to P in Figure 2B,
but when the T trajectory reaches P (i.e., when population T attains zero value), the
curve becomes horizontal, as all the tumour cells have become extinct, and thereafter,
the trajectory will follow the axis-line PEF onwards, where T remains zero throughout
as time elapses. The T population does not diminish further towards a negative value
as that is a biologically impossible feat. Further, we can treat the benign state of the
subject (without any tumour cells) as the target baseline condition, and hence the
Kapoor et al. Theoretical Biology and Medical Modelling 2013, 10:68 Page 7 of 34
http://www.tbiomed.com/content/10/1/68undesirable tumour cell population state T is considered as the tumour system devi-
ation or error ET from the benign condition. We define the error (Figure 2B) as
ET = (T – T*), and the error’s time derivative as ET′ = (T′ – T*′). Thus eq. (3) becomes
the error-equation which is calculated as:
ET ′þ κTET ¼ 0; implying T′–T′ð Þ þ κT T–T ð Þ ¼ 0 ð5Þ
Eq. (5) is derived by substituting the expressions of ET and ET′ above, in the error-equation. In eq. (5), the term T*′, i.e. the temporal rate of change of T*, is zero, since
value of T* is a pre-fixed constant (as decided by the experimenter). Thus, dropping
the term T*′ in eq. (5) furnishes the required tumour cell reduction rate for tumour
elimination:
T′ ¼ −κT T–T ð Þ ð6Þ
Eq. (6) is the condition for complete tumour regression, and hence should befollowed by the tumour cell compartment in Figure 1. Thereafter, proceeding upwards
through the successive compartments, such as administration of chemotherapy then
the immunotherapy, we can obtain the dose-time profiles of temozolomide,
interleukin-2 and tumour-infiltrating lymphocyte injections, for regression of the
tumour within the time duration td. Thereafter, the tumour shall not recur as there are
no surviving tumour cells. As a precaution, we continue the therapies for an extra suffi-
ciently long period before fully stopping.
We have earlier used the inverse solution approach, but without bias shifting, for two
treatment scenarios: (i) controlling chemotherapy infusion (imatinib) in myeloid
leukemia [16], and (ii) regulating therapeutic infusion for treatment of ionic metabolic
or hypocalceamic imbalance (control target error < 5%) [17]. In these cases the tumour
cell population regressed and the blood ionic level tended to approach the desired value
with high stability and asymptotically, but complete tumour elimination could not be
obtained at a definitive time. In the present paper, we have remedied this problem by
using adjustable bias shifting.
Computational model of multimodal therapy
We elucidate the quantitative approach for tumour dynamics under combinational
chemotherapy and immunotherapy (Figure 3), based on coupled ordinary differential
equations (ODE) between various cells and therapeutic agents. The approach is a broad
one, and can be generalized to common situations. In the current instance, we take the
case involving tumour cells, innate immunity cells (Natural killer cells), acquired im-
munity cells (Cytotoxic T-cells), and normal tissue protective cells (Circulating lympho-
cytes), along with antitumour therapies, including chemotherapy in the form of TMZ,
and immunotherapy, namely externally administered lymphocytes (tumour-infiltrating
lymphocytes) and lymphocyte-activating agents (as IL-2). The equations recollect the
experimentally-based immunological reaction-rate framework demarcated by de Pillis
et al. [18], Kuznetsov et al. [9] and Kirschner et al. [10], which has also been empiric-
ally validated [19]. The formulation also utilizes findings from animal studies and hu-
man clinical trials and uses models employed in cellular population biology,
incorporating reaction kinetics such as Michaelis-Menten type of interaction and satur-
ation processes as logistic functions.
Injected  Interleukin                 Interleukin in blood, I
     vi    
                        Tumour-infiltrating 
                       lymphocytes on blood
Injected Tumour- 
infiltrating lymphocytes           
vL
Chemotherapy in blo
Injected Chemotherapy:               M
DNA blockage
     vM 
      Cytotoxic T-cells in blood, L 
Tumour cells
od 





                     Tumour cell 
elimination
Natural killer 
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Figure 3 Interaction of multimodal therapy on the tumour and host system. Pointed and rounded
arrows denote the major facilitatory and inhibitory interactions respectively. Chemotherapy inhibits the
various cells, tumour cells being more susceptible. The major interactions are shown, and the minor ones
are mentioned in the text.
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model are graphically summarized in Figure 4 [eq. (S.1) to eq. (S.7) therein], and these are
elucidated in Additional file 1: Supporting Methods. In the formulas, the primed symbols
denote the temporal derivatives of the above entities (populations of the four types of cells,
or concentration of three therapeutic agents). The numerical values of the constant
parameters are obtained from experimental or clinical studies; values are given in Table 1.
Numerical values of the variables from the patient’s clinical data:
Regarding the variables in the left side of eqs. (S.1)-(S.7), N is the NK cell population, C
is circulating lymphocyte population, L is the cytotoxic T cell population in blood, M is
the chemotherapeutic drug concentration (in serum), I is the immunotherapeutic drug
concentration (in serum), and T is the tumour cell population in the tumour. One may
note that all these variables have definitive numerical values, which vary as time elapses
and therapy continues. These values can be calculated by solving the equations and
using the numerical values of parameters in the left side of eqs. (S.1)-(S.6). Some of
these parameters are related to the tumour cellular system:
(i) The pharmacological/cell birth/death/interaction parameters: a, b, c, d, e, f, p, m, q, u, r1, r2
(ii) Drug input/output parameters: α, β, γ, μ
(iii)Michaelis-Menten or saturation parameters: g, h, j, k, pI, gI, D, d, l, s;
(iv)Temporal lysis parameters of different cells: kT, kN, kL, kC.
The other parameters of the equations are related directly to the therapeutic agents:
(a)vM (t), vI(t), vL(t) are the daily injected dosages (input rate per day) of chemotherapy
(temozolomide), immunotherapy (interleukin-2), and cytotherapy (TIL cells) respectively.
Figure 4 Quantitative Formulation of the Multimodal Therapy.
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(c) l, the power-law exponent of fractional tumour cell kill by CD8+ T cells,
(d)s, the steepness coefficient of the cytotoxic T cell – tumour cell interaction curve
Stationary condition of the system in tumour elimination
The equilibrium points or stationary conditions of the system can be found by setting
the derivatives of the variables to zero, namely dT/dt =0, dN/dt = 0, dL/dt = 0, dC/dt =
0, in eqs. (S.1)-(S.4) respectively. Solving for the case t = 0, the equilibrium points are as
follows:
TE;NE; LE;CE½  ¼ 0; eα=βf ; 0; α=β½  ð6AÞ
This equation implies that there is a definitive tumour-free stationary state. At thisequilibrium point there is no presence of any malignant cell, i.e., the cytotoxic T-cell
population TE = 0, LE = 0, while there are specific levels of the immune cells, NK cells
and circulating lymphocytes, that correlate with the healthy state (NE = eα/βf, CE = α/β).
Substituting the values of the parameters α, β, e and f from Table 1 and taking the
Table 1 Values of the biological and pathophysiological parameters for the tumour system
Symbol Numerical value Characteristic significance Reference Units
Therapeutic parameters
p I 1.25 × 10
-1 Interleukin 2-induced CD8+T-cell recruitment rate (maximum value) Kirschner et al. [10] per day (rate value)
g I 2.00 × 10
7 Interleukin 2-induced CD8+T-cell recruitment (steepness value of the curve) Kirschner et al. [10] cell2 (cell-cell interaction)
μI 1.0 × 101 Decay rate of Interleukin-2 drug Kirschner et al. [10] per day
Birth/death parameters
α 7.5 × 108 Circulating lymphocyte birth rate (constant source) de Pillis et al. [18] cells per day
β 1.20 × 10-2 Lymphocyte death and differentiation rate de Pillis et al. [18] per day
γ 9.0 × 10-1 Chemotherapy drug decay rate Calabresi et al. [20] per day
kT 9.0 × 10
-1 Chemotherapy-induced tumour cell lysis Perry [1] per day
kN, kL, kC 6.0 × 10
-1 Chemotherapy-induced lysis of NK cells, CD8+T-cells, and Circulating lymphocytes, respectively Perry [1] per day
r1 1.1 × 10
-7 CD8+T cell generation rate, induced by tumour cell lysis by NK cell Yates et al. [21];
Lanzavecchia et al. [22]
per cell per day
r2 6.5 × 10
-11 CD8+T cell generation rate, induced by tumour cell - circulating lymphocyte lysis de Pillis et al. [18] per cell per day
Pathophysiological parameters
a 4.31 × 10-1 (high grade tumour);
3.01x10-1 (low grade tumour)
Rate of tumour growth Calabresi et al. [20]; Stein [23] per day
b 2.17 × 10-8 (high grade tumour);
1.02 × 10-8 (low grade tumour)
Deceleration effect of logistic growth of tumour Calabresi et al. [20]; Stein [23] per cell
c 6.41 × 10-11 NK cell-induced lysis of (non)-ligand-transduced tumour cell Diefenbach et al. [24] per cell per day
d 2.34 CD8+T cell-induced fractional tumour cell lysis (saturation value); priming by ligand-transduced cell Dudley et al. [25] per day
e 2.08 × 10-3 Lymphocyte fraction converting to NK cells Kuznetsov et al. [9] per day
f 4.12 × 10-2 NK cell death rate Kuznetsov [9] per day
g 4.98 × 10-1 Ligand-transduced tumour cell-induced NK cell recruitment rate (maximum value) Dudley et al. [25] per day



















Table 1 Values of the biological and pathophysiological parameters for the tumour system (Continued)
l 2.09 CD8+T cell-induced tumour cell lysis (exponent value) Dudley et al. [25] Dimensionless (exponent)
s 8.39 × 10-2 CD8+T cell-induced tumour cell lysis (Value of Steepness index of term D denoting lysis) Dudley et al. [25] Dimensionless (exponent)
p 3.42 × 10-7 Tumour-cell induced inactivation of NK cell Diefenbach et al. [24] per cell per day
m 2.04 × 10-1 CD8+T cell death rate Yates et al. [21] per day
j 2.49 × 10-2 Recruitment rate of CD8+T cells (max. value), cells primed with ligand-transduced tumour cells Diefenbach et al. [24] per day
k 3.66 × 107 CD8+Tcell recruitment curve (steepness index), cells primed with ligand-transduced tumour cells Diefenbach et al. [24] cell2 (cell-cell interaction)
q 1.42 × 10-6 Tumour cell-induced CD8+T cell inactivation rate Kuznetsov et al. [9] per cell per day
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rium population = 430,000 cells for the whole subject and circulating lymphocytes
population = 72 billion for the same. It is this equilibrium state that the system tends to
settle to, in the occasion of successful therapy.
System design formulation of multimodal therapy
In order to describe a system in terms of a control systems schema, we need to define the
internal parameters (state variables characterizing the condition of the tumour system) and
the external parameters (control parameters that can alter the tumour system). We formu-
late the ordinary differential equations (Figure 4), in terms of the control theory, whereby
(i) System state variables are the parameters indicating the internal biological
condition of host-tumour interaction in the patient. The system state variables in
this case are (1) Tumour cells (T), (2) Natural killer cells (N), (3) Circulating lym-
phocytes (C), (4) Cytotoxic T-Lymphocytes (L), as well as (5) blood concentrations
of Interleukin (I) and of (6) temozolomide chemotherapy (M) [Figure 1]. The state
variables are denoted as functions Xn, where n = 1 to 6.
(ii) Control variables of system include the parameter values the external
administrations of the three therapeutic agents, viz. the dose input rates of the
injected chemotherapy (temozolomide) and immunomodulants (interleukin-2 and
tumour-infiltrating lymphocytes), which are represented by vM (t), vI (t), and vL (t)
respectively. These parameters vary with time and are measured in body-weight
normalized rate units, e.g. in mg. of a drug per kg of body weight (or, per square
metre of body surface) of the patient, given per day. These control variables are
denoted as functions Um, where m = 1 to 3.
(iii)Constraint conditions of system indicate the quantitative requirements or
thresholds that cannot be crossed application of the therapy. All the state variables
need to be maintained within minimum and maximum values given in Table 2. For
instance, the minimum and maximum values of the different cellular parameters
should be within the physiological range that is necessary for homeostatic
maintenance of the internal environment, or milieu interne of the patient. Too
high a value of an entity can be toxic to the system, while, in some cases, there is a
minimum value required so that the host can have proper immune surveillance to
ward off foreign cells or microorganisms.
Using control systems practice, to construct the rate equation of any one particular
state variable Xp (a biological parameter), we express its time derivative or rate param-
eter Xp′, as a function of (i) the values of the various biological parameters that deter-
mine the system, namely Xn, and (ii) the effect of the proximal causal control variables
(drug factors, Um) on the biological variables (Xn).
We shall now explain the construction of the control design, in terms of objective,
operation and toxicity-minimization for each compartment.
Level 1: tumour cell compartment
Objective The aim is to find the desired values, M* and L* of this compartment’s
input parameters (Temozolomide blood level and Cytotoxic T-cell population), which
Table 2 Bound limits of biological and therapeutic parameters applicable to human cases
Parameter Lower limit Upper limit Reference
Circulating Lymphocyte, C (total population in the individual) 2.32 × 109 cells (for not more than
6 months duration)
4.5 × 1011 cells Macintyre et al. [26] (upper limit); Jarosz et al. [27] (lower limit)
Natural Killer Cells, N (total population in the individual) Negligible value (for not more than
3½ months duration)
5.85 × 1010 cells Berrington et al. [28] (upper limit); Jawahar et al. [29] (lower limit)
Tumour-specific cytotoxic (CD8+) T-cells (CTL), L
(total population of these cells in the individual)
Negligible value * 6.05 × 1010 cells Dudley et al. [25] (upper limit); Roitt et al. [30] (lower limit)
Temozolomide infusion dosage rate, vM 0 200 mg/m
2/day (4.45mg/kg/day) Perry [1]
Interleukin-2 infusion dosage rate, vI 0 7.2 × 10
4 I.U/kg/day Perry [1]
Tumour Infiltrating lymphocyte (TIL) cumulative dosage
(over full therapy duration, i.e., ∑ vL)
0 13.7 × 1010 cells Dudley et al. [25]
* This is applicable to the time after the tumour has been eliminated and pertains to population of the effective CD8+ T-cells specifically active against the particular tumour-lesion in the body; after tumour elimination,
there is no possibility of stimulation by tumour cells to initiate the generation of the active tumour-specific CTL. The various bound values in the Table can be relaxed by 10-15%, this relaxation in the limits of
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T*, until the T value becomes zero at point P in time tP (Figure 2B).
Operation of the compartment For the tumour cell compartment in Figure 1, we
construct the rate equation of the output state variable, tumour cell population T, by
expressing its time derivative T', in terms of
(i) the function fT (Xn) which denotes the values of the various biological
parameters that determine the tumour cell population system, namely the state
parameters Xn. This explains the tumour cell alteration function due to two
intrinsic biological (non-pharmacological) processes: (a) tumour cell growth
term, due to logistic or saturable growth, (b) tumour cell elimination term due
to natural killer cells.
(ii)the functions gT1 and gT2 that imply the biological effect of the compartment’s input
therapy variables that show a dose–response saturation behavior Ur , which is
produced by the two antitumour entities, cytotoxic T-cell population L, and temo-
zolomide concentration in blood, M.
Thus,
T′ ¼ f T þ gT1UM þ gT2UL½  ¼ f T þ bT ð7Þ
where UM and UL indicate the anti-tumour behavior or therapeutic efficiency of
Temozolomide and cytotoxic T-lymphocytes respectively, while bT denotes the
combined antitumour effect of these two therapeutic entities on tumour growth rate
T′ (Table 3). This antitumour behavior is quantitatively a saturation type of dose–
response function (like Michaelis-Menten function, Hill function or similar activity
function), which is a ubiquitous property of pharmacological responses. Thus Eq. (7)
which is equivalent to eq. (S.1) of Figure 4, can be written in terms of Michaleis-
Menten kinetics as,
T′ ¼ aT 1−bTð Þ−cNT−DT−κT 1−e−M
 
T ð8Þ
Comparing the right side of eq. (7) and (8),
f T ¼ aT 1–bTð Þ–cNT½ ; gT1 ¼ –kTT ; gT2¼–T ð9Þ
and
UM ¼ 1–exp –Mð Þ½ ; UL ¼ D ¼ d Ll= s T l þ Ll
 
: ð10ÞTable 3 Description of therapy system terms
Terms Description Reference formulation
UM Therapeutic efficiency factor of Chemotherapy UM = {1 − exp(−M)} [Eq. (10)]
UL Therapeutic efficiency factor of Cytotoxic T-lymphocytes UL = d L
l/(s Tl + Ll) [Eq. (10)]
UI Therapeutic efficiency factor of Interleukin-2 UI = pILI/(gI + I) [Eq. (27)]
bT Total tumour cell lysis effect from the two cytotoxic agents, Chemotherapy
(temozolomide) and Cytotoxic T-cells
bT = UMgT1 + ULgT2 [Eq. (12)]
bL Total cytotoxic T-cell activation effect from the two Immuno-modulating
agents, Interleukin and Tumour-infiltrating lymphocyte
bL = UI + vL [Eq. (29)]
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earlier, we use the previously described tumour growth rate as T′ = −κT (T – T*). [One
may take care to distinguish this kappa parameter, κT, the tumour decay rate (due to
multimodal therapy), from the cytolysis rate parameter kT of eq. (S.1) due to chemo-
therapy only]. Putting this expression of T′ = −κT (T – T*) in eq. (7), we obtain the
condition that needs to be followed to induce complete tumour regression:
f T þ gT1UM þ gT2UL ¼ –κT T–T ð Þ ð11Þ
Rewriting eq. (11), we obtain the terms containing the pharmacological effect func-tions gT1 and gT2:
gT1UM þ gT2UL ¼ bT ð12Þ
where,
bT ¼ –κT T–Tð Þ–f T ¼ – κT T–T ð Þ þ f T½  ð13Þ
Eq. (12) furnishes the relationship of the blood concentration of the antitumouragents (UM and UL), which, if implemented, will ensure that the tumour cells undergo
complete extinction.
Transposing the eq. (13),
f T þ κT T–Tð Þ þ bT ¼ 0 ð14Þ
Eq. (13) implies that, for proper therapy, the combined therapy-induced anti-tumour
effect term, bT , should take care of two aspects: (i) the condition required for enforcing
tumour cell population elimination, i.e. the expression -κT (T – T*), and (ii) the tumour
cell growth due to biological processes, i.e. fT (Table 3). At each time point, as tumour
cell population changes, the cytotoxic therapy drive term bT alters. Eq. (13) indicates
that the relaxation decay term bT has negative value if tumour is to regress (or bT has
value zero, if the tumour becomes arrested at a definitive volume and thereby becomes
stable), thus here bT ≤ 0. From eq. (12):
gT1UM þ gT2 UL− bT ¼ 0 ð14AÞ
Eq. (12) furnishes the relationship of the blood concentration of the antitumouragents (UM and UL), which, if implemented, will ensure the tumour cells undergo
complete extinction.
Minimization of toxicity of antitumour therapy However the blood concentra-
tions UM and UL also needs to be regulated in such a way so that the combined toxicity
effect on the patient is minimal. Hence we now need to minimize the normal tissue
damage cost function due to the agents. Using the quadratic cost concept (see earlier
“Background” section), we have the cost function for the tumour cell compartment as:




Here rT1 and rT2 are the weighting factors of the two therapeutic entities, temozolo-mide and cytotoxic T-cells. The cost function JT needs to be minimized, and at the
same time eq. (12) should be obeyed as a constraint. The minimization of the cost
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2 + rT2 UL
2], is evidently a constrained optimization problem,
and the optimality can be customarily solved by the method of Lagrange multiplier, λ.





 þ λ gT1UM þ gT2UL–bT
   ð16Þ
where the right sided expression within the second brackets {….} in eq. (16) incorpo-
rates the left side of the constraint equation [eq. 14(A)], as required by the Lagrange’s
method. To pursue the minimization of the augmented cost function, we differentiate J
with respect to the two variables UM and UL. Thereby, we find out the minimization
conditions, i.e., ∂J/∂UM = 0, and ∂J/∂UL = 0, whence we get the expressions for the two
variables:
Temozolomide efficiency term,
UM ¼ bTgT1=r1G ð17Þ




   ð19Þ
Further, from eq. (10):UM ¼ 1−exp −Mð Þ½  and UL ¼ d Ll= s T l þ Ll
  ð20Þ
Desired input values of the therapy levels Solving the two equations of the last
line, we obtain the desired values, M* (blood concentration of temozolomide) and L*
(cytotoxic T-cell population):
M ¼ –ln 1–UMð Þ; and L ¼ s T lUL= d–ULð Þ
 1=l ð21Þ
In the last two equations, for the terms UM and UL, we substitute their values from
eq. (17) and (18) respectively. Thence, we arrive at the desired values of the temozolo-
mide blood level and cytotoxic T-cell population, which, if implemented, will regress
the tumour fully:
Desired temozolomide blood level:
M ¼ –ln 1– bTgT 1=rT 1G
  
; ð22Þ
Desired cytotoxic T-cell population:
L ¼ – sT l bTgT 2=rT 2G
 
= d– bTgT 2=rT 2G
   1=l ð23Þ
Level 2: cytotoxic T-cell compartment
Objective Here the goal is to find the desired values, I* and vL*, of this compart-
ment’s input parameters (interleukin-2 blood level and tumour-infiltrating lymphocyte
injection dose-rate), which would drive the compartments output, namely the cytotoxic
T-cell population, L to its desired value L* mentioned in the last paragraph. This enforced
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and requires to be done till time tr, point P, when all the tumour cells have become
eliminated (Figure 2B).
Operation of this compartment We use the methodology of guided tracking
principle of control systems analysis, which we have already used for the tumour cell
population compartment [eq. (5)]. Likewise, we enforce the situation of the cytotoxic
T-cell population L obeying the condition EL′ + κL EL = 0, where κL is a positive parameter
and the deviate EL = (L – L*). Using similar logic of the reduction of the deviate or error
[eq. (6)], we obtain:
L′ ¼ −κL L–Lð Þ ð24Þ
We recollect the characteristic rate formulation of the tumour cell compartment,
T′ = fT (Xn) + bT [i.e. eq. (7)]. We now desire to formulate the characteristic rate formu-
lation of the cytotoxic T-cell compartment in terms of L′. Thus, we express the temporal
dynamics equation of L′ [Eq. S.3 of Figure 4)] as:
L′ ¼ f L Xð Þ þ UI þ vL ð25Þ
where vL is the tumour-infiltrating lymphocyte injection dose-rate, UI is the therapeutic
efficiency relationship of interleukin-2, and f(Xn) is a system function expressing the T-
cell immunomodulation, viz. the biological and pharmacological variables, acting on
this cytotoxic T-cell population. Compare eq. (25) with eq. (S.3) that states:
L0 ¼ dL=dt
¼ −mLþ Lj D2T 2 = k þ D2T 2  −qLT
þ r1N þ r2Cð ÞT−uNL2−LkL 1−e−M
 þ p1LI= g1 þ Ið Þ þ vL tð Þ ð26Þ
By this comparison, one notes that UI, the term dealing with interleukin level I, can
be identified as:
UI ¼ pILIð Þ= gI þ Ið Þ ð27Þ
and one can also express
f L Xð Þ ¼−mL
þ jD2T2= κ þ D2T 2
 
L−qLT
þ r1N þ r2Cð ÞT−uNL2–LκL 1−e−M
  ð28Þ
Eliminating L′ from eq. (24) and eq. (25), we note that
UI þ vL ¼ bL ð29Þ
WherebL ¼ −f L Xð Þ–κL L–Lð Þ ð30Þ
Note here that fL(X) is the performance function of the cytotoxic T-cell compartment,
a part of the the right-side of the eq. (26) except its last two terms, which are the
therapy-input terms, dependent on the interleukin and tumour-infiltrating lymphocyte
injected, the two terms being denoted as bL, In eq. (26), the last term vL is the Tumour-
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denoted as UI, is the therapeutic efficiency relationship of interleukin-2. Evidently from
eq. (26), the term bL signifies the total cytotoxic T-cell activation effect by the two immu-
notherapeutic inputs: the interleukin efficiency term UI and the tumour-infiltrating
lymphocyte administration term vL (Table 3). Indeed, the said equation indicates that the
relaxation decay term bL has positive value if the tumour regresses (or zero, if the tumour
is arrested and thereby stable), i.e. bT ≥ 0. Actually, eq. (29) furnishes the relationship of
the characteristics of the antitumour agents, interleukin and tumour infiltrating lympho-
cytes (UI and vL), which if implemented, will ensure the full elimination of tumour.
Minimization of toxicity of antitumour therapy In this compartment, the two
antitumour agents are nterleukin-2 and Tumour-infiltrating lymphocytes. As explained
for the earlier compartment, we need to minimize the toxicity cost function for the com-
partment where the two therapeutic input functions arriving at the compartment are
Interleukin-2 (i.e., its efficiency function UI) and tumour-infiltrating lymphocyte (its injection
dose-rate, vL). The cost function for this compartment is:
JL ¼ 1=2 rL1UI2 þ rL2vL2
  ð31Þ
where rL1 and rL2 are the sensitivity weights due to the two aforesaid therapeutic moi-
eties in this compartment. For minimization, the constraint requirement [UI + vL = bL]
from [eq. (29)] should be obeyed. Solving using the Lagrange multiplier method, we ar-
rive at:.
Interleukin-2 efficiency term,
UI ¼ bL=rL1 H ð32Þ
Tumour-infiltrating lymphocyte injection dose-rate,vL ¼ bL=rL2 H; ð33Þ
where
H ¼ 1=rL1ð Þ þ 1=rL2ð Þ½  ð34Þ
Desired input values of the therapy level By transposing UI = {(pI LI)/(gI + I)}
[i.e., eq. (27)], we obtain the desired value of I* (blood concentration of Interleukin-2):
I ¼ gIUI= pIL–UIð Þ ð35Þ
Substituting UI from eq. (32) to eq. (35), we get the desired value of tumour-infiltrating lymphocyte injection dose-rate which will eliminate the tumour:
Desired interleukin-2 blood concentration,
I ¼ gIbL= pIL rL1H–bLð Þ ð36Þ
Level 3: temozolomide injection compartment
Objective Here the goal is to find the desired value, vM*, of this compartment’s input
parameter (temozolomide injection dose-rate), which would drive the compartment’s
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given in eq. (22). This driving needs to be done faster than the preceding compartment
(T-cell compartment), and is to be done by time tp, point P (Figure 1).
Operation of this compartment We need to implement the condition that
EM′ + κM EM = 0, where the deviate EM = (M – M*). Using similar reasoning as the
earlier compartment, we get M′ = −κM (M – M*). Eliminating M′ from this equation
and from eq. (S.5), we have:
Desired temozolomide injection dose−rate vM ¼ γM–κM M–Mð Þ ð37Þ
Level 4: interleukin-2 injection compartmentThe condition necessary to be implemented is that EI′ + κI EI = 0 where the deviate
EI = (I – I*) Thus, I′ = −κI (I – I*). By eliminating I′ using eq. (S.6), we note:
Desired interleukin−2 injection dose−rate; vM ¼ μI I–κI I–Ið Þ ð38Þ
Level 5: tumour-infiltrating lymphocyte injection compartmentFor this compartment, we can write from eq. (33) that:
Desired tumour−infiltrating lymphocyte injection dose−rate; vL ¼ bL=rL2 H ð39Þ
Determining tumour regression rate constant, bias shift and therapeutic weights
Delineating the rate parameters κT, κM, κL, κI and bias T*
These are rate constants of the tumour cell compartment, temozolomide compartment,
cytotoxic T-cell compartment and interleukin compartment, respectively, as regression
occurs under the action of multi-modal therapy. These are calculated from the desired
rate of tumour regression, expressed as settling time ts of the regression process (the
time duration in which 90% of tumour has regressed), and is taken to be around 1–2
months. The tumour regression rate constant κT = 4/ts; so if ts is 60 days, κT = 0.067
per day. On the other hand, the dynamics of the successively preceding compartments
(e.g. chemo-therapy and cytotoxic T-cell compartments) need to be faster, as they caus-
ally influence the tumour cell compartment, and thus need to change more rapidly if
they are to have a controlling influence on the tumour cell compartment (Figure 1).
Thus, the time constants of the modular stages will be lesser, and hence the process
rate constant will be higher. So, we can choose the rate constants κL and κM of cyto-
toxic T-cell compartment and temozolomide injection compartment respectively, such
that they exceed κT. Similarly, the rate constant κI of interleukin compartment (that
causally acts on the T-cell compartment), is chosen to be higher that κL.
Thus,
κL; κMð Þ > κT ; and κI > κL:
As explained earlier, in control analysis [15], a thumb rule used is: rate constantsbetween two successive stages in a cascade control system are in the ratio of 1: 3. Thus,
Kapoor et al. Theoretical Biology and Medical Modelling 2013, 10:68 Page 20 of 34
http://www.tbiomed.com/content/10/1/68if we have the value of rate constant of the tumour cell population, κT and then we
obtain the value of the other constants in terms of κT :
κL ¼ 3κT ; κM ¼ 3κT ; κI ¼ 3κL; i:e:; κI ¼ 9κT ð40Þ
In the above example, since, κT = 0.067/day, we get κL = 0.201/day, κM = 0.201/day,and κI = 0.603/day. It may be noted that the tumour elimination time tp (Figure 2) when
100% tumour has regressed, is longer than ts, and can be selected as 10 days more, i.e.
tp = 70 days. If the initial pre-therapy tumour cell population is estimated as T0 , then
substituting the values of T0, κT and tp in the right-sided expression in eq. (4), provides
the value of bias shift T*.
Selection of therapeutic weights rT1 , rT2 and rL1 , rL2
These adaptable parameters, rT1, rT2, rL1, rL2 are needed for minimizing the toxicity
cost of the therapy. It is these parameters that give a control to the investigator for
maneuvering the tumour elimination process, under adjustable dosing of the drugs. Ini-
tially, the values of the tuning parameters rT1, rT2, rL1, rL2 which appear in derivation,
are chosen by specific quantitative conditions (see Additional file 2: Supporting Ana-
lysis). To recapitulate, rT1 and rT2 are respectively the toxicity cost weighting factors of
temozolomide and cytotoxic-T-cell, acting on the tumour cell population compartment,
producing the cost JT which is to be optimized.
For such optimization problems, it is known that the important characteristic to be
considered is the ratio rT1: rT2 [15]. Thus, we can take the parameter rT1 to have a nor-
malized value of unity (i.e. rT1 = 1), thereby the task is to suitably choose or optimize
the value of the other tuning parameter rT2. Correspondingly, rL1 and rL2 are respect-
ively the toxicity cost weighting factors of interleukin-2 and tumour-infiltrating lym-
phocytes, which act on the cytotoxic T-cell compartment and produces the toxicity
cost JL. Similarly, this cost can be minimized by normalizing rL1 = 1, and then optimiz-
ing rL1. All the tuning parameter values must be greater than or equal to zero. Using
the upper and lower bounds that needs to be followed by the cellular and pharmaco-
logical variables (Table 2), we can calculate the numerical values of the therapeutic
weight parameters (Additional file 2: item B.3 and Table 1 there).
Efficiency of different combinations of therapeutic agents
During the analysis and modeling procedure, the control variables, i.e. parameters of
the therapeutic agents, should have positive values and not attain negative nor imagin-
ary values, even though the system dynamics [eq. (S.1-S.7)] has fractional exponent at
some places [eq. (S.7)]. The situation is amended in case if any of the computed control
variables, or of the three injected drug dosage rates calculated (vM*, vI* or vL*), becomes
imaginary or negative. If this happens, the particular drug injection rate (say, for drug-A)
is stopped and kept suspended (its dosage is henceforth taken to be zero), the simula-
tion is continued with the presence of the other two drugs. As long as the dosage of
the drug-A calculated remains negative or imaginary, drug-A is not injected, and the
drug A’s value for the subsequent simulation steps becomes zero, while the other
two drugs, whose calculated dosages continue to be positive numbers, are continued to
be administered. Only when the computed dose of the drug-A turns positive, then the in-
jection of drug-A is resumed according to that dose. To wit, the following alternative
situations occur:
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duration: If so, all are given.
(ii) One drug becomes negative or imaginary for a particular time interval: this drug is
stopped during that interval, and the other two drugs are continued as per the
modeling procedure with the first omitted
(iii)Two drugs become negative or imaginary: here the remaining drug with a positive
drug dosage rate is administered.
(iv)All the three drugs violate the positivity condition: then no drug is given, until one
or more drug rates become positive at a subsequent time, upon which the
administration of the drug/s is resumed.
If case (ii) is applicable, then there will be three different combinations for two drugs
at a time by permutation: (a) temozolomide and interleukin, or (ii) temozolomide and
tumour infiltrating lymphocytes, or (iii) interleukin and tumour infiltrating lympho-
cytes. If case (iii) is relevant, then the three possibilities are: temozolomide or interleu-
kin or tumour infiltrating lymphocytes. The mathematical formulation for cases (ii) and
(iii) are derived later (Additional file 2: item B.4), using the overall approach of case (i)
presented above. Further, once the tumour cell count becomes zero (point P, Figure 2B)
by any of the above approaches, one stops the drug/s thereafter. The overall method-
ology of our approach is shown in Figure 5.
Results and discussion
Numerical simulations for tumour elimination
We computationally model the tumour system dynamics using custom-made coding
and solve in the MATLAB platform [eq. (7)-(14A)], and thereby obtain the temporalFigure 5 Flow sheet of multimodal therapy to actuate full elimination of tumour cells.
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respectively furnish the temporal profile of temozolomide, interleukin-2 and tumour-
infiltrating lymphocytes, which would eliminate the tumour cell population. In Figure 6
we develop the detailed procedural steps into a readily-usable algorithm toolkit. Our
concern is the general problem of neurooncology, especially neuroectoderm originating
tumours such as glioma, melanoma or neuroblastoma, which are comparable tumours,
biologically and pharmacologically, and respond to similar therapeutic interventions, as
temozolomide, interleukin-2 and lymphocyte immunotherapy by T-cells [1,5,20,32,33].
Now we apply the proposed approach to regressing both slowly and rapidly growing
tumours, astrocytoma grade II and astocytoma grade III respectively, aiming at a time-
frame of about 2 months. We take the values of parameters of the equations from ex-
perimental clinical studies available or from general oncological investigations (Table 1).
The values of the parameters can be applied to tumours in general, for example to tu-
mours of neuroepithelial origin, as melanoma or neuroma, or sarcoma [9,19,24]. Actu-
ally, using values of such parameters from clinical or pre-clinical tumour model
systems, one can solve differential equations of tumour response under drugs or im-
mune cells, and the mathematical predictions are closely confirmed and validated by
cytological measurements on human subjects during therapy [19,34,35].Figure 6 Steps of Multimodal Therapy Algorithm for Tumour Elimination.
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We consider the realistic case of low-grade tumour as ologidendroglioma or glioma
grade II tumour with initial conditions of starting malignant cell population (T0) of 2 × 10
7,
natural killer cell population of 105, cytotoxic T-cell population of 5 × 104 and circu-
lating lymphocytes of 109 cells (see endnote b before the References). From this T0
value, we get a bias shift T* = 1.8986 × 105 cells [right-side of eq. (4)] (see subsection on
“Determining tumour regression rate constants” above). All the other constants used in
the model are given in Table 1, with the tumour cell growth rate, a = 0.301 per day, and
the deceleration rate of logistic tumour growth b = 1.01x10-8. We start the simulation
procedure increasing the temporal step by one minute each time (Figure 7), and find









Figure 7 Induction of complete elimination of low-grade tumour under multimodal therapy,
inversely reconstructed with bias shift: oligodendroglioma tumour. (A) Tumour cell population as
therapy progresses, population becomes zero at point P, after 30.1 days, system tracked for 70 days
(point L), to ensure complete elimination of the cells and no relapse of them occurs. Inset shows plot for
800 days, tumour cells population remains zero indefinitely. (B) Temporal variation of the Cytotoxic CD8+
lymphocyte population needed for complete elimination of tumour. Note bimodal temporal dose-profile with
two peaks, occurring at two time points, A and B. (C) Temporal profile of concentration of chemotherapy agent
Temozolomide required to eliminate the tumour. Observe unimodal temporal dose-profile with hump D,
thereafter drug level decreases to E; (D) Level of Interleukin-2 concentration needed for tumour regression. Note
the substantial level of interleukin, the level being truncated so as to keep concentration level below its toxicity
threshold (point F level). (E) Natural killer cell population during therapy. Population stops increasing duly, 600
days plotted to show this and population does not cross upper bound of physiological limits in Table 2. (F)
Circulating lymphocyte population, also does not exceed upper bound of physiological limits (Table 2). (G) Injected
daily dose-rate of tumour-infiltrating lymphocyte required for tumour elimination. Arrow demarcates pulse dosage
injection (point G) needed at latter portion of the therapy. Distinct step G readily seen in enlarged inset (arrow).
(H) Injected daily dose-rate of Temozolomide chemotherapeutic drug necessary for tumour regression, dose-rate
does not rise above H, so as to be below toxicity bound (Table 2). Arrow points to pulse dosage injection required
later. (I) Injected daily dose-rate of Interleukin-2 required for eliminating the tumour, dose-rate also kept at
permissible upper limit (Table 2). Arrow shows elevated pulse dosage injection needed later.
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desired time duration, tp. This duration is different from the initially planned tumour
elimination time tp, since, during simulation there may be time durations when a
drug is stopped [this happens if its dose is calculated to have a negative or imaginary
value [Figure 6, item (M)]], but the other drugs are increased with sufficient intensity to
ensure tumour cell lysis at a substantial level. These increased therapeutic dosages can
have nonlinear cell-killing effects and thus produce a shorter tumour elimination time
than expected. It may be noted that we perform the computation for a time span of 20
times the extinction period (i.e. span of 800 days), a sufficiently long time to check per-
manency of regression. The regression appears to be lasting without any re-appearance
of tumour cells, even though the therapy had been stopped much earlier (Figure 7A). It
may be noted that for our plots or records, we take the computed cellular population
values to have the next integer numeral, e.g. if N, C, T or T* is calculated out to be
1230.23 cells, the value is taken to be 1231 cells.
We also plot the blood concentrations of the cytotoxic T-cells, chemotherapeutic
agent temozolomide and interleukin-2, required to eliminate the tumour (Figure 7B-7D).
Also displayed are plots of the population of circulating lymphocytes and NK cells to
check that there is no significant toxicity as side-effects of the therapy (Figure 7E-7F).
We also observe that these values are also well within the corresponding bounds
of the human host system (Table 2). Finally Figure 7G-7I show the injected dose rates,
as required, day-wise, for each of the three therapeutic agents, that enables full tumour
elimination. The circulating lymphocytes and NK cells takes around 500 days to reach
the steady state values of 76 billion and 510,000 cells respectively. Note that these
values closely corroborate with the stationary points solved theoretically earlier, which
are 72 billion and 430,000 cells respectively [see eq. (6A) and subheading “Stationary
condition of the system” there]. We find that the extreme values of these variables in
the graphs are well within the bounds of the human host system (Table 2). For
instance, the maximal dose-rate of temozolomide chemotherapy and of tumour-
infiltrating lymphocytes are less than 10% and less than 1% respectively, of the upper
bound of these agents in Table 2. Further, the cumulative dose of the interleukin (from
the dose-rate graph calculated as area under the curve in Figure 7D), is below 1% of
the interleukin upper bound in Table 2.
High-grade tumour
For the faster growing tumour such as astrocytoma or glioma grade III, we take tumour
cell growth rate, a = 0.431, which is about 50% higher than the low-grade glial tumour
discussed above. An initial malignant cell population (T0) of 2 × 10
7, natural killer cell
population of 105, cytotoxic T-cell population of 5 × 104 and circulating lymphocyte of
109 cells were considered to simulate the system. The same tumour settling time and
tumour elimination time-line is given, and a bias of T* = 1.8986 × 105 cells is taken. The
other parameters for the tumour system are given in Table 1. We proceed with the
numerical simulation and observe that the tumour cells become extinct at 40.11 days
(Figure 8A). Since the tumour cell proliferation rate, a value is higher here than the
earlier tumour, the current tumour needs more treatment duration than the former.
Likewise, we perform the computation for a time span of 800 days, to ensure the perman-









Figure 8 Induction of complete elimination of low-grade tumour under multimodal therapy,
inversely reconstructed with bias shift: astrocytoma III. (A) Tumour cell population as therapy
progresses, the population becomes zero at point P, after 40.11 days, the system is tracked for 800 days in
the inset figure, to confirm the full extinction of tumour cells without any relapse over a period of 800 days.
(B) The temporal variation of the Cytotoxic CD8+ lymphocyte population needed for full regression of
tumour. One discerns the bimodal temporal dose-profile with two peaks at A and B. (C) The temporal
profile of Temozolomide concentration necessary for tumour elimination. There is evidently an unimodal
temporal dose-profile with the hump D, thence the chemotherapy level diminishes to point E; (D) The level
of Interleukin-2 concentration required for extinction of the tumour cells. One notes the substantial level of
interleukin (F), with truncation so as to have the level below the toxicity limit of interleukin in Table 2.
(E) Natural killer cell population, N that does not cross the upper bound of physiological limits (Table 2).
(F) Circulating lymphocyte population, C that can also be maintained below the upper bound of physio-
logical limits (Table 2). (G) Injected daily dose-rate of Tumour-infiltrating Lymphocyte which is necessary for
tumour elimination. An elevated pulse dosage injection essential at the latter part of the therapy, is delineated
by arrow. (H) Injected daily dose-rate of Temozolomide chemotherapy that is requisite for the tumour regres-
sion. The pulse dosage injection required at the latter duration of the therapy, is shown by an arrow. (I) Injected
daily dose-rate of Interleukin-2 that is needed for the extinction of tumour cells. An arrow shows the pulse dosage
injection (point G) needed at the terminal portion of the therapy.
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around 0.33 million and 62 billion cells respectively (Figure 8E-8F). These correspond to
the stationary state populations predicted mathematically earlier. As in the earlier case of
slow-growing tumour, one can also note the same for the rapidly-growing tumour:
(i) the dosages of the therapeutic agents drops to zero from the tumour extinction
time onwards
(ii) none of the cell populations or dosing of therapeutic agents crosses the bounds
(Table 2), and
(iii) the dosages of the three agents are approximately the same fraction of the upper
bound (10%, 1% and 1%).
We also discern that the therapy period is considerably longer in high-grade tumour,
basically since the tumour growth rate is about 50% more than the slow-growing
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a much smaller fraction of the upper bounds, the dosage profile can be well tolerated
by patients. Actually, the overall patterns of the graphs (Figures 7 and 8) are compar-
able, across both the high and low grade tumours.
Robustness of tumour elimination procedure
The values of the parameters used are taken from Table 1. However these biological system
parameters can vary across individuals, depending on the physiological and constitutional
of the patient. Hence we need to check that the methodology is applicable even though the
parameters may vary along a range. In order to test the versatility and robustness of our
approach, we varied the initial immunological status (values of N, C, L cells) and tumour
system parameters (values of tumour growth rate, α and carrying capacity, β). We per-
formed 500 random simulations to check for complete tumour elimination, in both
tumour grades. We found that tumour extinction for oligodendroglioma occurred in 100%
cases if the variation was 0%, and in 98% of the cases as the coefficient of variation was in-
creased to 10% (Table 4). For astrocytoma, the results are comparable. It has been known
that the physiological parameters are generally kept constant homeostatically by organisms,
with a 10% variation around the mean level [31]. Thus we can ascertain that the proposed
approach may be able to induce tumour elimination in the large majority of cases.
Unitary pattern in tumour regression process
If one compares the corresponding graphs in Figures 7 and 8, there are evident similar-
ities in the temporal profiles of the therapeutic agents needed in both high-grade and
low-grade tumours to enable elimination of malignancy. The common patterns valid
across both tumours are elucidated below.
Profile A: terminal therapy pulse and cytotoxic lymphocyte persistence
One notes that (i) no injections of any of the three therapeutic agents are required
any time after the time point of extinction of tumour, which does not recur later
(Figure 7G-7I and Figure 8G-8I); (ii) the blood levels of the three therapeutic agents and
the populations of the natural killer cells and circulating lymphocyte stay within the
requisite limits, assuring that there would be no significant toxicity to the patient
(Figure 7B-7F and Figure 8B-8F). One can make two pertinent observations from the
simulation results. Firstly, for one to make the exponential decay curve of tumour cell
population hit the T = 0 baseline (i.e. the x-axis of Figure 2B) at a definitive time point
tp , one needs to inject a terminal pulse of each of three therapeutic dosages before the
end of treatment protocol in both the low-grade and high-grade tumours, as shown byTable 4 Robustness study with biological parameter variation
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pulses of all three agents ensure that in the last stage, all the tumour cells in the expo-
nential extremity of cell population decay curve, do become eliminated. Secondly, the
persistence of the cytotoxic T lymphocytes in blood for a over a week after tumour has
been eliminated (Figures 7B and 8B), can have a beneficial effect, such that it can act as a
vigilant anti-tumour measure against recurrence, by acting for an appreciable time after
tumour extinction. After that duration elapses, this lymphocyte population tapers off.
Profile B: common temporal paradigm of therapeutic agents needed
An insight into the mechanism of tumour regression may be obtained by investigating
the commonalities in the pattern of the temporal variation in the blood levels of the
therapeutic agents and population of the protective cells, which seem to be common
across both high-grade and low-grade tumours. From Figure 7B-7D and Figure 8B-8D,
we discern the following temporal patterns of the aforesaid entities, the pattern being
similar for both rapidly and slowly growing tumours:
(i) Temozolomide concentration (chemotherapy): monophasic activation pattern
The curve of M is unimodal for both low-grade and high-grade tumours, steadily rising
initially, and later, gradually tapering off (Figures 7C and 8C). This chemotherapy con-
centration curve follows the usual pharmaco-kinetic curve of a customary drug admin-
istration: a unimodal hump, with gradually rising drug concentration to point D, and,
later gradual concentration reduction (Figure 9A shows overall pattern).
(ii) Cytotoxic T-lymphocyte (CTL) concentration (cytotherapy): biphasic activation pattern
This graph has bimodal peaks for both the high-grade and low-grade tumour
(Figures 7B and 8B, arrows; Figure 9B). We observe that for tumour elimination, there is
a need to have a peak of CTL, both, around the initial and the final phases of the therapy.A Monophasic Activation Function        B Biphasic Activation Function     
Concentration of entity                                                                         
(chemotherapy: temozolomide)                                            
C Stationary Activation Function D Saturating Activation Function
Concentration of entity                            
(interleukin-2)                                                   
Time                                                           Time
Time Time
Population of entity





Figure 9 The common pattern template of required activation functions of input factors associated
with complete tumour regression. (A) Unimodal intensity of chemotherapy (temozolomide). (B) Bimodal
intensity of leucocyte immunotherapy (cytotoxic lymphocyte). (C) Uniform truncated intensity of cytokine
immunotherapy (interleukin-2). (D) Saturating intensity of the tissue protective entities: natural killer cells
and circulating lymphocytes.
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the cancer cell population curve (T) towards the zero baseline (Figures 7A and 8A). The
final peak concentration of CTL, occurs before the time of tumour elimination, and is ne-
cessary to sufficiently eliminate the tumour cells and depress their population trajectory
so that the same hits the zero baseline at the definitive selected time point P (Figure 1B).
Depending on the tumour system dynamics, the height or activation-level of the second
peak may be lower (Figure 7B), or higher (Figure 8B), than the height or activation-level
of first peak. In case of Cytotoxic T-cell concentration, the first peak is due to therapeutic
agents of tumour-infiltrating lymphocytes and interleukin, whose dosing starts as an im-
pulse stimulus from the initial time. The impulse of these agents also enhance the gener-
ation of CTL population. The second peak in cytotoxic T-cells (point B in Figure 8B)
occurs due to the later dip or decay of chemotherapy concentration along the hump of
the M curve (point K in Figure 8C). The chemotherapeutic agent is toxic to and dimin-
ishes all the cellular constituents, including CTLs, and, hence, a decrease of chemotherapy
induces a rise of CTL then. This same pattern of primary and secondary induction of
T-cell population also occurs in the other tumour (Figure 7B-7C).
(iii) Interleukin-2 concentration (immunotherapy): stationary activation pattern
This agent is needed at a substantially high level (at the upper bound, just below tox-
icity level), so as to induce a higher level of immune activation that would enable
complete elimination of glioma cells (Figures 7D, 8D and 9C). Indeed it is well known
from clinical experience in neurooncological immunotherapy that interleukin-2 admin-
istered at significantly augmented dose, induces long-lasting immunomodulation to act
against those malignant cells that bypass usual therapeutic intervention [36]. Actually,
the graph for the high- and low-grade tumours has rapidly rising high amplitude, as
the interleukin-2 level is truncated and kept stationary within toxicity limit.
(iv) Circulating lymphocyte population: saturating activation pattern
This population initially increases and then plateaus in both tumours (Figures 7F, 8F
and 9D), to approach the saturation level of the long-term steady state as mentioned
earlier.
(v) Natural killer cell population: saturating activation pattern
Similar to the Circulating lymphocytes, the NK cells show saturation behaviour for
both high and low grade tumours (Figures 7E, 8E and 9D).
Experimental, biological and clinical corroboration
To justify, the modus operandi of our approach is based on the following aspects:
firstly, the tumour elimination process is a manifestation of exponential diminution
with bias shifting; secondly, the procedure works on fundamentally two complimentary
modes of tumour cell reduction:
(a)Reducing the tumour cell proliferation, as by chemotherapy or chemical alkylation
(DNA damage);
(b)Increasing the tumour cell lysis by anti-tumour lymphocytes, which are activated by
cytokine modulation (for instance tumour infiltrating lymphocytes, interleukin-2 etc.).
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tumour entities should have three distinct temporal profiles: (1) biphasic intensity for
lymphocyte activation, (2) monophasic intensity for activation of chemomodulative
DNA damage (chemical alkylation), (3) stationary intensity of cytokine activation (inter-
leukin-2). The experimental studies in animals [37-39] and clinical situation [40,41]
corroborate these findings. Thus our results show that complete elimination of tumour
can be attained by (i) the five-pattern profile: activation of antitumour lymphocyte (bi-
modality), chemomodulative DNA damage (unimodality), interleukin (stationary), nat-
ural killer cell (saturation), and circulating lymphocyte (saturation), (ii) the two kinetic
conditions: bias shift and exponential decrementing dynamics [the tumour trajectory
formula of eq. (4)].Translational applicability
There are two aspects where the approach could be improved. Firstly, one can increase
the system robustness, which diminishes as the individual patient-specific fluctuations
increases (see earlier subsection on Robustness). For real-time implementation, we can
use the neuro-adaptive controller, which can reliably follow the desired mathematical
trajectory of the tumour cell population curve (Figure 2B), and can be well adapted to
different values and fluctuations of biological parameters of different patients. We have
used such a controller in devising imatinib chemotherapy dosing in chronic myeloid
leukaemia [16], and 100% robustness was obtained even when the maximal tumour
density varied from 150,000 to 400,000 cells/mm3, indicating about 250% variation on
the baseline level. Secondly, for proper monitoring of a patient, the declining tumour
load T can be weekly or semiweekly estimated non-invasively, by MRI amide-proton
transfer imaging, which maps the cell proliferation intensity by amide mobility [42].
This emerging technology holds high potential, as this method is an efficient one to
distinguish between various oncological conditions such as tumour recurrence, tumour
haemorrhage or tumour necrosis.
In Figure 7A the tumour cell diminution trajectory is shown for the subject in ques-
tion, the cell population being mathematically derived given the physiological parame-
ters. It would be preferable if one could check this mathematically obtained curve T(t)
with the actual real-life tumour cell population T(t) as the treatment process goes over
months, the actual population T(t) being estimated radiologically at suitable discrete
time intervals of τ (Figure 10). The aim is to have correction-making feedback so that
the actual realistic curve T tracks and follows the desired computationally-optimized
curve T. In case if there is a discrepancy at a particular time point tk, between the
actually-measured value and the mathematically-predicted value (i.e. between T and T
at time point tk), then the value at that moment of the actual number of tumour cells
Tk can be used as the input value of tumour cell population at time point tk in the
simulation procedure for going to the next time point tk+1 as per the procedure in
Figure 6. Thereby, the new dosages of the drugs can be calculated for reaching the
same target, namely zero population of tumour cells. The result is that the actual tra-
jectory of the diminution of the tumour cell population becomes a discrete approxima-
tion of the continuous mathematical curve, with the time interval τ (Figure 10).
Nevertheless, the final target of zero tumour cell population is attained.
Figure 10 Clinical implementation of tumour elimination procedure, using MRI-based tumour-load
monitoring method at weekly time intervals. The multimodal therapy starts from point A and its effect
on the malignant tissue is monitored by estimating the tumour load (correlate of tumour variable T) using
MRI amide proton-transfer imaging, done at time intervals of τ. The blood levels of the therapeutic agents
and of its cell populations (circulating lymphocytes, natural killer cells, cytotoxic T-cells etc.) are also measured
then. These data are used to give corrective feedback to the therapy system in case there is incongruity
between the actual trajectory and the mathematically calculated trajectory desired. Data sampling at τ and any
uncertainty or instability of the biological parameters, are taken care by Kalman’s filtering and neuroadaptive
control which actuates the infusion pump of the therapeutic inputs to the patient.
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tervals, the overall measurements of the serum temozolomide and interleukin-2 levels,
as well as the populations of cytotoxic T-cells, natural killer cells and circulating
lymphocyte in the blood (Figure 10). Only approximate values of these parameters or
of the tumour cell population are required, as even large variations of these parameters
can be accommodated by the neuro-adaptive controller mentioned above. During prac-
tical implementation, it may not be possible to measure all the biological parameters,
neither a parameter can be estimated at all the desired time points as there may be
discontinuous or missed sessions. Here, one can use suitable quantitative procedures as
the Kalman’s technique or constraint filter method which has been used in immun-
ology to estimate the likely values of biological parameters at the discrete or missed
sessions, given their measured values in other sessions [43,44]. Thus, it would suffice to
monitor the tumour parameters weekly or twice-weekly, to enable the therapy control
system tracking and adapting function, as demarcated in Figure 10.
One may observe that during therapy (Figures 7E-7F and 8E-8F), the circulating lym-
phocytes and natural killer cells increase but there is no hazard, as the populations are
within the upper physiological limits of Table 2. Moreover, for making the methodology
more suited to personalized medicine so that we can pre-select the most sensitive drugs
beforehand, we can utilize the emerging method of tumour-graft technology whereby
one can grow a therapeutically faithful model of the individual patient’s tumour biopsy
tissue on experimental mice [45]. Tumour graft platforms can test different drug com-
binations, and pre-select the most sensitive drug before starting the treatment, the
Kapoor et al. Theoretical Biology and Medical Modelling 2013, 10:68 Page 31 of 34
http://www.tbiomed.com/content/10/1/68accuracy of selecting effective drug molecule being 86%. Lymphocytic (CTL) immuno-
modulation can be of tactical utility, as it exhibits a range of unique behaviors [46], that
chemotherapeutic drugs cannot, such as (i) the cells can migrate to the antigen-bearing
primary or secondary growths of tumour, even in hidden tissue depths, (ii) CTLs can
continue to multiply automatically in response to immunogenic proteins of malignant
cells, until all those cells become extinct.
Conclusion
We have formulated the distinctive dose-time relationship of chemotherapy and of im-
munotherapy (interleukin-2 and cytotoxic lymphocyte), such that their orchestrated func-
tioning, that incorporates a biphasic temporal profile for T-cell, ensures that all the tumour
cells are eliminated within a desired time. Excess toxicity to the host is avoided, as the
circulating lymphocyte and natural killer cells in blood are protected. The approach
is patient-specific as the formulation depends on the tumour load, the levels of cytotoxic
T lymphocytes, cytokine interleukin, natural killer cells and circulating lymphocytes. All
these parameters vary with the individual patients, and hence the different therapeutic
dose-time profile obtained for each specific patient will be optimally suited from her. The
formulation put forward use of an innovative approach of bias shift, control systems ana-
lysis, performance cost minimization and inverse construction of drug input. The limita-
tion of the proposed model is that we have not considered the effect of tumour cells
resistant to the chemotherapy drug and also not taken care of angiogenesis process where
the drug permeability to the tumour cells will hinder. A broad-based gamut of findings
from animal experimentation and clinical investigations are shown to corroborate with
the tumour extinction approach developed. An unanticipated but noteworthy finding is
the importance of giving a terminal pulse of the therapeutic agents before the end of the
therapy, so that all the tumour cells become extinct and there is no extra drug-induced
toxicity, the natural killer cells and circulating lymphocytes being within the physiological
limits. This is in contrast to the generally prevailing view in clinical medicine, which advo-
cates tapering off of the therapy in the later stages. This tapering may cause tumour recur-
rence in clinical praxis, as there is no intensive spike of the therapeutic agents to eradicate
all the malignant cells.
To summarize, information from temporal dynamics of both the endogenous and ex-
ogenous tumour regression has been used to explore the mechanism and elucidation of
integrative functioning of various therapeutic modalities, whose combined effect elimi-
nates the malignant tumour as corroborated with experimental findings. The method
proposed can be of wide-ranging application, and can be adapted for application to
conditions where there is involvement of chemotherapy and/or immunotherapy. The
procedure delineated is also applicable to other tumour systems, as it offers a principled
approach to tumour containment and thus an incisive prospect for probing towards
further biological and clinical situations.
Endnotes
a Clarifications on upper/lower limits of biological and therapeutic parameters
(Table 2).
Circulating lymphocyte population: The normal blood volume under active circula-
tion is 3.5-4.5 litres. The higher limit of lymphocytes in individuals can be up to 100 ×
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higher bound of lymphocyte in a person to be 4.5 × 1011 cells. In contrast, the lowest
lymphocyte count for patients for duration of 6–12 months across therapy can be 663–
1160 cells/μl [27]. Taking the lesser value of the cell count and the lower level of blood
volume, we get minimal bound of lymphocytes as 2.32 × 109 cells, which the patient
can tolerate up to 6 months.
Natural Killer Cells population: The upper limit of NK cell is 13% of lymphocyte
population, with CD56/CD16 surface protein being the marker for these lymphocytes
[28]. As the higher bound of lymphocyte population in the earlier paragraph is 4.5 × 1011
cells, we have the maximum value of NK cell population in the individual to be 5.85 ×
1010 cells. On the other hand, the lower limit of NK cells (CD56/CD16 lymphocytes) is
0, occurring in people having natural killer cell deficiency condition [29], and a period of
3½months have been noted for elapse of this condition, before considerable infection
can set in [29]. Hence we also mention this time duration for the NK cells lower bound.
Tumour-specific Cytotoxic (CD8+) T-cell population: The upper limit of this cell popu-
lation for a patient is 20150 cells/mm3 [25]. Using a blood volume of 4.5 litres, the total
T-cell (CD8) population will be 6.05 × 1010 cells. Furthermore, tumour-specific cytotoxic
T-cells, that are specifically active against a particular malignant lesion, has been known
to come into play if the tumour is present, and to decay away if the tumour undergoes
elimination [30]. Hence, one mentions the lower bound of these T cells to be 0.
Temozolomide chemotherapy infusion dosage rate: Maximum daily dosage [1] of tem-
ozolomide is 200 mg/m2/day, i.e., 4.45 mg/kg body. wt. per day. One may choose not
to give it, so the lower limit is 0.
Interleukin-2 immunotherapy infusion dosage rate: Maximum infusion given is 7.2 ×
104 International Units (I.U.)/kg/day [1]. The lower bound can be set to nil, as above.
Tumour-infiltrating lymphocytes (TIL) immunotherapy cumulative dosage: The max-
imum cumulative dose for a patient over the whole duration of therapy is 13.7 × 1010
cells [25]. Likewise, the lower limit is zero.
b Determination of initial number of the cells for numerical experimentation.
Tumour cells: The number of cells in a tumour which becomes clinically detectable is 108
occupying a volume of 1 cm3, out of these 107 cells are malignant, while the rest are stromal
cells [47]. For our quantitative experimentation, we take double the amount of tumour cells
to have a safety factor of 2, thus giving 2 × 108 malignant cells as our initial condition.
Circulating lymphocytes: We also note the range of normal values: leucocyte count =
4000 to 11000/mm3, the fraction of lymphocytes are 15-40%, and actively pulsating
blood volume under circulation is 3.5-4.5 litres. To be cautious for ensuring tumour re-
gression, we will consider the lower values in the range. By multiplying the requisite
aforesaid values, we have the circulating lymphocyte population in the person as 2.1 ×
109 cells. Again to be on safer side, we take half of the population for our study (i.e.
1.05 × 109 cells, say 109 cells).
Natural killer cells: The fraction of NK cells is 1-13% of circulating lymphocytes [28],
we take the lower value for calculation, and use the circulating lymphocyte value of 1 ×
109 cells given above. Further, there is available data on the antitumour effector factor
of NK cells during study of endogenous tumour regression, namely 1:50 as target
tumour cell: effector NK cell ratio, i.e. a value of 2% [48]. Multiplying these values, we
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will consider half this value to be on the safe side, i.e. NK cell population = 105 cells.
Cytotoxic T-cells: The fraction of cytotoxic CD8+ T-cells is 1-3% of circulating lym-
phocytes [49]. The cytotoxicity factor of activated tumour-infiltrating cytotoxic T cells
(CTL) is 9.5% as regression process is underway [48]. One also knows that if the
tumour is invasive and spreads, the fatigue factor come into force, which can cause the
CTL efficiency (as estimated by cytokine production) to decrease to 12.2% of the level
as compared to when there is no invasion of tumour [50]. Using these factors, we arrive
at the effective population of cytotoxic T cells as 1.15 × 105 cells, say 105 cells. As per
the lower end, we have taken half, i.e. 5 × 104 cells as the CTL population.
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